Confidence in Dendreon ON Call

From questions about insurance coverage to patient financial assistance, Dendreon ON Call provides comprehensive support for PROVENGE therapy.

Rapid and Comprehensive Benefits Verification

Dendreon ON Call provides your patients and practice with a dedicated case manager to:
  • Complete enrollment, benefits verification, and patient assistance eligibility checks within 48 hours*
  • Conduct an insurance verification to confirm each patient’s coverage and out-of-pocket costs
  • Determine coverage for government-insured, commercially insured, or uninsured patients
  • Initiate the patient financial assistance process for uninsured patients
  • Contact independent foundations for patients who may need financial or treatment-related travel assistance

*Missing information may delay the 48-hour turnaround.

Commitment to Patients With Limited Financial Resources

Dendreon ON Call is committed to supporting you

Co-pay assistance

Eligibility is determined by
Dendreon
  • Refers Medicare patients to the appropriate independent foundation that may provide financial assistance for co-pays, co-insurance, and deductible costs
    Eligibility is determined by the individual foundation
  • Commercially insured patients may be eligible to access PROvide, which provides coverage of up to $6,000 for PROVENGE treatments
Support for
uninsured or rendered
uninsured patients


Eligibility is determined by
Dendreon

PROVENGE is provided free of cost to eligible uninsured patients and those eligible patients who have become uninsured due to a final payer claim denial.§

Requirements include:

  • Adjusted gross income of $150K a year or less
  • Age 18 or older
  • US resident
  • On-label prescription
Travel cost assistance
  • If you need financial assistance with treatment-related costs, a case manager can refer him to independent resources to determine if he is eligible for help with these costs

*Co-pay and travel assistance foundations provide assistance regardless of the choice of medicine, and decisions are based on financial need and according to criteria established by the individual foundations. Dendreon ON Call can assist patients by referring them to these independent organizations. Dendreon cannot guarantee that patients will be eligible for or receive assistance after referral. Dendreon does not have control or managerial influence over these independent organizations.

†The PROvide Commercial Co-pay Program provides flexible coverage of up to $6,000 over 3 PROVENGE treatments for co-pays, co-insurance, and deductible costs. Eligibility criteria can be changed or program can be discontinued at any time at the sole discretion of Dendreon. Patients with government-funded insurance including Medicare, Medicare Part D, Medicaid, or TriCare are not eligible for the PROvide Program. Additional terms and conditions apply.

‡ Contact Dendreon ON Call at 1-877-336-3736 for eligibility criteria. Uninsured patient assistance program eligibility criteria can be changed or program can be discontinued at any time at the sole discretion of Dendreon.

§ In the event an eligible patient’s claim for coverage for PROVENGE is denied by his payer after all appeals, the cost of the drug may be covered by Dendreon’s patient assistance program.


Learn More About Treatment Scheduling

INDICATION

PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.

IMPORTANT SAFETY INFORMATION

Acute Infusion Reactions: Acute infusion reactions (reported within 1 day of infusion) may occur and include nausea, vomiting, fatigue, fever, rigor or chills, respiratory events (dyspnea, hypoxia, and bronchospasm), syncope, hypotension, hypertension, and tachycardia.

Thromboembolic Events: Thromboembolic events, including deep venous thrombosis and pulmonary embolism, can occur following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events. PROVENGE should be used with caution in patients with risk factors for thromboembolic events.

Vascular Disorders: Cerebrovascular events (hemorrhagic/ischemic strokes and transient ischemic attacks) and cardiovascular disorders (myocardial infarctions) have been reported following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events.

Handling Precautions: PROVENGE is not tested for transmissible infectious diseases.

Concomitant Chemotherapy or Immunosuppressive Therapy: Chemotherapy or immunosuppressive agents (such as systemic corticosteroids) given concurrently with the leukapheresis procedure or

PROVENGE has not been studied. Concurrent use of immune-suppressive agents may alter the efficacy and/or safety of PROVENGE.

Adverse Reactions: The most common adverse reactions reported in clinical trials (≥ 15% of patients receiving PROVENGE) were chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Click here for Prescribing Information.